(Q33232404)

24 July 2017

1 reference

title

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines (English)

1 reference

24 July 2017

1 reference

Eleni Aklillu

2

0 references

Vural Özdemir

1

object named as

Vural Ozdemir

1 reference

24 July 2017

4

Leif Bertilsson

1 reference

24 July 2017

Steven Mee

3

1 reference

24 July 2017

Lawrence J Albers

5

1 reference

24 July 2017

Janice E Graham

6

1 reference

24 July 2017

Michael Caligiuri

7

1 reference

24 July 2017

James B Lohr

8

1 reference

24 July 2017

Christopher Reist

9

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Pharmacotherapy

24 July 2017

published in

1 reference

24 July 2017

volume

7

1 reference

24 July 2017

issue

2

1 reference

24 July 2017

page(s)

119-133

1 reference

Oxidative mechanisms and tardive dyskinesia

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Association of diabetes with dyskinesia in older psychosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Tardive dyskinesia and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Clinical implications of pharmacogenomics for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

What has been the impact of the concept of essential drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

The concept of essential medicines: lessons for rich countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Global health and justice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Tailored medicine: whom will it fit? The ethics of patient and disease stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Rhetoric and hype: where's the 'ethics' in pharmacogenomics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Some new hope but still no hype for academic psychiatry in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.119

21 January 2018

Identifiers

DOI

10.1517/14656566.7.2.119

1 reference

24 July 2017

1 reference